- Home
- NMRA vs DBD Comparison
NMRA vs DBD Comparison
Compare NMRA & DBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMRA
- DBD
- Stock Information
- Founded
- NMRA 2019
- DBD 1859
- Country
- NMRA United States
- DBD United States
- Employees
- NMRA N/A
- DBD N/A
- Industry
- NMRA
- DBD EDP Services
- Sector
- NMRA
- DBD Technology
- Exchange
- NMRA Nasdaq
- DBD Nasdaq
- Market Cap
- NMRA 1.7B
- DBD 1.6B
- IPO Year
- NMRA 2023
- DBD N/A
- Fundamental
- Price
- NMRA $1.91
- DBD $42.38
- Analyst Decision
- NMRA Strong Buy
- DBD Strong Buy
- Analyst Count
- NMRA 6
- DBD 2
- Target Price
- NMRA $20.67
- DBD $57.50
- AVG Volume (30 Days)
- NMRA 3.9M
- DBD 89.0K
- Earning Date
- NMRA 03-06-2025
- DBD 02-12-2025
- Dividend Yield
- NMRA N/A
- DBD N/A
- EPS Growth
- NMRA N/A
- DBD N/A
- EPS
- NMRA N/A
- DBD 0.00
- Revenue
- NMRA N/A
- DBD $3,799,000,000.00
- Revenue This Year
- NMRA N/A
- DBD $0.73
- Revenue Next Year
- NMRA N/A
- DBD $1.58
- P/E Ratio
- NMRA N/A
- DBD $13,783.17
- Revenue Growth
- NMRA N/A
- DBD 2.88
- 52 Week Low
- NMRA $1.81
- DBD $30.02
- 52 Week High
- NMRA $21.00
- DBD $51.81
- Technical
- Relative Strength Index (RSI)
- NMRA 21.73
- DBD 42.32
- Support Level
- NMRA $1.81
- DBD $42.22
- Resistance Level
- NMRA $2.02
- DBD $43.74
- Average True Range (ATR)
- NMRA 0.15
- DBD 1.24
- MACD
- NMRA 0.27
- DBD -0.04
- Stochastic Oscillator
- NMRA 19.61
- DBD 27.46
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.
About DBD Diebold Nixdorf Incorporated Common stock
Diebold Nixdorf Inc is engaged in providing software and hardware services for financial and retail industries. The customer segments of the company are banking which offers integrated solutions for financial institutions and retail which offers solutions, software, and services which improve the checkout process for retailers.